Please login to the form below

Not currently logged in
Email:
Password:

Bispecific antibodies

This page shows the latest Bispecific antibodies news and features for those working in and with pharma, biotech and healthcare.

Trial failure for bintrafusp alfa casts doubt on GSK/Merck KGaA’s cancer alliance

Trial failure for bintrafusp alfa casts doubt on GSK/Merck KGaA’s cancer alliance

Bispecific antibody fails in non-small cell lung cancer trial. Bintrafusp alfa – the novel immunotherapy at the centre of a major alliance between GlaxoSmithKline (GSK) and Merck KGaA – has failed in ... Bintrafusp alfa is part of a new wave of

Latest news

More from news
Approximately 5 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    It hopes to break into the big league with the launch of its own proprietary product by 2025 in addition to a string of collaborations based on its novel antibodies. ... In addition to traditional antibodies, the pipeline also includes antibody drug

  • Deal Watch December 2016 Deal Watch December 2016

    511. BioInvent (Sweden). Pfizer (US). Research collaboration. Development of immuno-regulatory antibodies targeting tumour-associated myeloid cells. ... Technology. Merus. Incyte. $3, 000m. $120m plus $80m equity. Bispecific antibodies.

  • Deal Watch September 2016 Deal Watch September 2016

    In return, Zymeworks is licensing immuno-oncology antibodies from Daiichi Sankyo, in exchange for royalties on sales. ... 624. EngMab / Celgene. Acquisition corporate. T cell bispecific antibodies that bind simultaneously to a tumour antigen and the T

  • Deal Watch June 2016 Deal Watch June 2016

    2 T-cell engaging XmAb bispecific antibodies: XmAb14045 for AML and XmAb13676 for B-cell malignancies (preclinical) and other rights. ... licence. 125. EpimAb Biotherapeutics/ Innovent Biologics. Fabs-In-Tandem immunoglobulin platform to develop multiple

  • Deal Watch April 2016 Deal Watch April 2016

    The collaboration provides GSK with a platform technology to develop bispecific antibodies. ... 125 . Enumeral (US). Pieris (DE). License &option to further programme. Discovery state 388D4 programme of PD1 Monoclonal Antibodies immunotherapies.

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

  • F-star hires ex-BMS immuno-oncology leader

    Dr Kayitalire’s background will be of benefit to F-star, as it looks to advance its bispecific antibody pipeline in oncology. ... pipeline. As we saw at the recent ASCO meeting, bispecific antibodies are leading a paradigm shift in cancer care and the

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics